Introduction
It is known that thyroid hormones are associated with the redox-balance homeostatic regulation.
Indeed, thyroid dysfunctions increase lipoperoxides which is an autocatalytic mechanism leading to oxidative damage of cellular membranes (1) . Such damage may bring about cell death and to the production of toxic and reactive aldehyde metabolites, where malondialdehyde (MDA) is the most important. Subclinical hypothyroidism (SH), defined as an elevated serum thyroid stimulating hormone (TSH) level associated with serum thyroid hormone concentrations within the reference range, has been reported to affect 4-10% of Western populations (2, 3) . Moreover, although depression of metabolism due to hypothyroidism has been described to decrease oxidant production and thus theoretically protecting tissues against oxidative damage, clinical evidences point out, on the contrary, that patients with hypothyroidism have an increased risk of developing atherosclerosis (4) and SH is also considered either experimentally and clinically a definite risk factor for overall cardiovascular aging and disease (5, 6) . Accordingly, there are several data associating an hypothyroid status to enhanced oxidative stress (7) (8) (9) . However, this issue is far from being completely settled in that, for instance, when hypothyroid rats were treated with 3,3,,5-triiodothyronine (T3), a significant increase in the level of oxidative stress parameters in mitochondrial fraction (MF) was recorded in adult rat brain (10) . However, hydrogen peroxide content of MF as well as post-mitochondrial fractions of cerebral cortex was elevated by inducedhypothyroidism and reverted to normal level by subsequent treatment of T3. Indeed, when applying thyroid hormone supplementation (THS), it should be considered that T3 exerts calorigenic action by accelerating mitochondrial O 2 consumption through the triggering of the transcription of respiratory genes, which enhances reactive oxygen species (ROS) production. Existing data suggest that THS calorigenesis is reached by either a short-term nongenomic signaling mechanism mediated by 3,5-diiodothyronine and T3 leading to the allosteric stimulation of cytochrome-c oxidase and also a long-term pathway upregulating nuclear and mitochondrial gene transcription via T3
signaling. This respiratory factor accounts for up to 25% of the net increase in total O 2 consumption and, as a matter of fact, increased ROS is also a feature of hyperthyroidism (11) . Thus, it is not surprising the finding of a very recent study suggesting that oxidative stress in subjects with primary hypothyroidism under therapy with L-T4 might be the cause of the side effects following L-T4 therapy in relation to oxidative stress (12) . This might one of the reasons behind the discomfort and loss of working activity often experienced in these patients not considering also further potential ROS-mediated subclinical phenomena to be manifested on the long run. When 
Material and Methods
Patients. 60 generally healthy females, aged 18-55, not on birth pill control or soy supplement.
Exclusion criteria were: main chronic diseases, relevant medications, major dislipidemia disorders, heavy physical activity and psychiatric disorders. All subjects presented with SH or MH and had been previously found to have normal level of zinc, selenium and copper.
Patients were put on a 2-week wash-out period and then divided into two groups (30 each) matched as for age, routine biochemical status, dietary profile and thyroid status assessment. Both groups received similar medical treatment for their hypothyroidism. One group was given: FPP 3gr 1 sachet twice-a-day for 3 months while the other group was given a flavored sugar sachet as placebo.
A matched group of normal thyroid function subjects was our healthy control (HC). Moreover, the 
RNA isolation and thyroid receptors gene expression analysis
Total 
Results
No reduced intake of main dietary trace minerals and vitamins appeared from the dietary questionnaire data while lipid profile and thyroid hormone parameters remained unchanged and unaffected by FPP supplementation (data not shown). As compared to HC a significant increase of all oxidative markers was observed in MH subjects (p<0.05) but not in SH. Treatment with T4 brought about a further increase (p<0.05 vs baseline) in MH and a significant increase also in SH subjects. While placebo was ineffective, FPP-supplemented individuals showed a significant normalization of redox markers in all tested subjects (p<0.01). As compared to baseline symptom score, treatment with FPP showed a non-significant trend improvement (n.s). However, at the entry only 6 (20%) subjects in the placebo group and 8 (27%) in the FPP-treated group reported symptoms affecting their quality of life. Although the limited number didn't allow a deeper analysis, interestingly all 3 subjects in the FPP-treated group reporting a long-standing gastrointestinal discomfort often requiring to lower the dosage of the T3 therapy when cyclically being prescribed this in association to their established T4, reported a complete recovery. THS cased a significant down-regulation of TRα-1 mRNA (p<0.01 vs baseline) but not of TRβ-1 genes and this pattern was unaffected by FPP. It appears that not only FPP can counteract the thyroid hormone-induced oxidative stress but it does not impair the physiological primary hormone-related receptors. This may be speculatively advocated for by a possible enhancement of the inner mitochondrial efficiency due to better antioxidant mechanisms and avoiding the weakening antioxidant defense as shown by Zhang et al (17) . It remains mandatory to implement a careful tailor-made THS because even limited increases of TSH may allow considerable health benefits (18). However, given the failure of vitamin C to counteract the associated redox-inbalance during THS (19), these findings prove that FPP intervention might be an advisable integrative treatment to be associated to long-standing THS 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
